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A B S T R A C T    
Pure RBC aplasia (PRCS) is a well-recognized complication after allogeneic hematopoietic stem cell trans- 
plantation (HSCT). Many therapeutic options are available to treat this condition, including erythropoietin, 
      rituximab, bortezomib, plasma exchange, immunoadsorption, donor lymphocyte infusion, mesenchymal stem 
cells, antithymocyte globulin, and high-dose steroids; however, treatment outcomes are often variable and 
can sometimes lead to disappointing results. In this brief article we report our experience with 2 patients 
with PRCA after major ABO-incompatible HSCT who were resistant to multiple therapeutic interventions and 
who eventually benefited from treatment with eltrombopag, a thrombopoietin mimetic approved by the US 
Food and Drug Administration for the treatment of patients with immune thrombocytopenic purpura or severe 
aplastic anemia refractory to immunosuppressive agents or not eligible for HSCT. Data from these 2 patients 
show that eltrombopag was effective in treating erythroid aplasia and transfusion dependence after HSCT in 
patients who did not benefit from multiple previous treatments. Moreover, eltrombopag was well tolerated, 
with only a transient thrombocytosis requiring dose adjustment and no evidence of clonal evolution. Based 
on the positive results obtained in these 2 patients, we suggest that eltrombopag may have a favorable effect 
on unilineage cytopenias such as PRCA. Further studies in a large proportion of patients are mandatory to 
confirm these preliminary results. 
 
 
 
 
 
INTRODUCTION 
Pure RBC aplasia (PRCA) is an uncommon complication of 
ABO major mismatched allogeneic hematopoietic stem cell 
transplantation (HSCT), occurring in 7.5% to 16% of patients 
[1-4]. PRCA has been considered as the result of B lympho- 
cytes of recipient origin producing isohemoagglutinins, which 
can interfere with the engraftment of donor erythroid cells, 
and is characterized by delayed RBC recovery after trans- 
plantation, anemia, and reticulocytopenia [5]. 
The diagnosis is confirmed by the absence of erythro- 
blasts from otherwise morphologically normal bone marrow, 
once other causes, for instance viral infections and drug tox- 
icity, have been excluded. A number of risk factors have been 
associated with the development of PRCA, including anti-A 
isoagglutinins, the use of reduced-intensity conditioning, 
 
cyclosporine-based graft-versus-host disease (GVHD) pro- 
phylaxis, the absence of GVHD, and grafts from matched 
sibling donors [3-5]. 
Although several patients may recover spontaneously, 
others need more aggressive treatment strategies to avoid ex- 
tensive RBC transfusions and related iron overload [6]. Rapid 
tapering of immunosuppressive agents, erythropoietin (re- 
combinant human erythropoietin [rHuEPO]), rituximab, 
bortezomib, plasma exchange (PEX), immunoadsorption, 
donor lymphocyte infusion, mesenchymal stem cells, 
antithymocyte globulin, and high-dose steroids have been 
used for treatment of PRCA; however, results reported in the 
literature with these therapeutic options are largely vari- 
able or even disappointing in many cases [3,6-18]. 
Eltrombopag is an oral thrombopoietic receptor agonist 
that is approved by the US Food and Drug Administration 
for the treatment of patients with immune thrombocytope- 
nic purpura [19,20] and severe aplastic anemia (SAA) 
refractory to immunosuppressive treatments or not eligible 
for HSCT [21-23]. We hypothesized that eltrombopag might 
have activity in patients with PRCA based on the favorable 
multilineage responses observed in patients with SAA, par- 
ticularly with extended therapy [22]. Here we report our 
experience with the use of eltrombopag for the treatment 
 of 2 patients with PRCA after major ABO-incompatible 
HSCT. 
 
RESULTS 
Between January 2012 and July 2017, 321 patients with 
hematologic disorders underwent an allogeneic HSCT at the 
Stem Cell Transplant Center of the AOU Citta’ della Salute e 
della Scienza of Turin. Eight of 97 (8%) assessable patients 
receiving major (n = 76) or bidirectional (n = 21) ABO- 
incompatible grafts developed a PRCA. In 2 patients a prompt 
erythroid response was observed after 3 and 5 cycles of PEX, 
respectively, in 1 case associated with rHuEPO; 3 patients re- 
sponded to rHuEPO alone. One patient failed to demonstrate 
a response to PEX and rHuEPO, and eventually PRCA re- 
solved after 4 doses of rituximab. Two patients who developed 
PRCA resistant to multiple therapeutic interventions are herein 
described. 
 
Patient 1 
A 48-year-old man with high-risk acute myeloid leuke- 
mia (FLT3 positive with NPM1 mutation and extramedullary 
involvement) in first complete remission received a periph- 
eral blood HSCT from an HLA matched unrelated donor in 
January 2016. The conditioning regimen was myeloablative, 
and GVHD prophylaxis consisted of antithymocyte globu- 
lin, cyclosporine, and short-course methotrexate. Donor and 
recipient blood groups were A negative and O positive, re- 
spectively. Pretransplant anti-A isohemoagglutinin titer was 
1:512. RBC reduction of the apheretic product was not per- 
formed because of the low hematocrit value. 
Neutrophil and platelet engraftment occurred on days +16 
and +17 post-HSCT, respectively. The patient received the last 
RBC unit on day +13. However, since day +37 the patient de- 
veloped a transfusion-dependent anemia, with remarkable 
reticulocytopenia (.09% absolute value) and a transfusion 
need of about 2 RBC units every week; however, anti-A 
isohemoagglutinin titer was still 1:512. 
On day +47 the patient started treatment with theta- 
erythropoietin (EPO) 40,000 U/wk, with any appreciable 
response after 6 weeks of treatment. On day +90 the bone 
marrow biopsy documented the presence of a PRCA, with a 
global cellularity of about 50%, whereas WBC and platelet 
precursors were well represented. Viral infections (cyto- 
megalovirus; Epstein-Barr virus; human herpesvirus-6, -7, and 
-8; herpes simplex virus 1 and 2; and parvovirus B19) were 
excluded. Neither signs of hemolysis nor iron or vitamin de- 
ficiencies were detected. On day +120 reticulocytopenia was 
still present, and anti-A isohemoagglutinin titer was 1:256; 
neutrophils were at the lower normal value, whereas the 
number of platelets dropped to 24,000/mm3. No clinical signs 
of acute GVHD were present. 
Because of a persistent lack of erythroid response, the 
patient received 5 PEX procedures from day +124 every other 
day. Theta-EPO 40,000 U was administered after each PEX 
and then continued weekly for 3 weeks. PEX procedures 
were rather well tolerated, except for an episode of 
hypofibrinogenemia treated with plasma replacement. After 
PEX procedures the anti-A isohemoagglutinin titer dropped 
to 1:64; however, no erythroid response was observed. 
At 6 months post-HSCT iron chelation therapy (ICT) with 
deferasirox (DFX) was started with a ferritin value of 4437 ng/ 
mL. On day +234, rituximab 375 mg/m2/wk was administered 
for 4 consecutive weeks, together with theta-EPO 40,000 U 
once a week. However, the treatment did not result in any 
beneficial effect in terms of transfusion dependence, 
reticulocytopenia, or thrombocytopenia. DFX was temporar- 
ily withheld because of a high creatinine value and grade 3 
neutropenia requiring granulocyte colony-stimulating factor 
administration, and the patient was eventually switched to 
deferoxamine (DFO) after 100 days of treatment. Eleven 
months post-HSCT, rHuEPO was definitively stopped due to 
lack of response. 
At 1 year post-transplant bone marrow biopsy showed a 
dishomogeneous representation of myeloid and erythroid 
lineage with mild megakaryocytic hyperplasia; global cellu- 
larity ranged from 10% to 60%, and chimerism was 100% full 
donor. because of the presence of a pancytopenia, we decided 
to start the thrombopoietin (TPO) mimetic eltrombopag at 
the dose of 75 mg/day for the first 2 weeks and then in- 
crease to 150 mg/day. After 1 month of treatment the patient 
showed a significant increase of neutrophils and platelets and 
a reduction of transfusion support to 1 RBC unit per week. 
After 2 months of treatment the patient was independent 
from transfusions, with a hemoglobin value of 11.3 g/dL and 
normal neutrophils and platelets counts. After 4 months of 
treatment eltrombopag was discontinued with a hemoglo- 
bin value of 15.4 gr/dL; thrombocytosis has never been 
observed. 
At the present, the patient has been off eltrombopag treat- 
ment for 8 months by now with normal hemoglobin levels 
and neutrophil counts. The bone marrow biopsy showed a 
normal cellularity (80%) with good trilinear representation. 
No cytogenetic abnormalities have been detected. Figure 1A 
shows the time course of patient 1. 
 
Patient 2 
A 47-year-old woman with biphenotypic acute leuke- 
mia in first complete remission received an allogeneic 
peripheral SCT from an HLA matched unrelated donor in 
January 2015. Myeloablative conditioning regimen con- 
sisted of cyclophosphamide and total body irradiaiotn 12 Gy, 
and GVHD prophylaxis was based on antithymocyte globu- 
lin, cyclosporine, and short-course methotrexate. The blood 
groups of the patient and the donor were O positive and A 
positive, respectively. 
The patient’s anti-A isohemoagglutinin pretransplant titer 
was 1:256. RBC reduction of the apheresis stem cell product 
was not performed because of the low hematocrit value. 
The patient reached neutrophil and platelet engraft- 
ment on days +24 and +18 post-HSCT, respectively. The last 
RBC unit was transfused on day +14. Since day +37 hemo- 
globin values gradually decreased, and the patient became 
transfusion dependent (2 RBC units every 2 weeks). On day 
+47 treatment with theta-EPO (rHuEPO) 40,000 U per week 
was started; WBC and platelet values were normal, reticu- 
locyte count was 5700 × 109/L, neither iron or vitamin 
deficiency nor hemolysis was detected, and EPO value was 
25 U/L. No remarkable response was seen after 6 weeks of 
treatment with rHuEPO. 
A bone marrow biopsy on day 100 was consistent with 
the diagnosis of PRCA with a normal representation of myeloid 
and platelet precursors and a global cellularity of 70% 
(Figure 2A). Full donor chimerism was detected, and the bone 
marrow aspirate demonstrated a complete remission of her 
underlying disease. Based on these findings, together with 
the persistence of an anti-A isohemoagglutinin titer of 1:64, 
on day +112 a course of PEX was started. Unfortunately, the 
patient developed a severe anaphylactic reaction to plas- 
matic proteins that led to the immediate discontinuation of 
the PEX program. 
  
 
 
Figure 1. Evolution of hemoglobin level (solid line) and ferritin levels (dotted line). The treatments with their influence on hematologic parameters are illus- 
trated in patient 1 (A) and patient 2 (B). RTX indicates rituximab; BRT, bortezomib; CTX, cyclophosphamide. 
 
 
At 5 months post-HSCT ICT with DFX was started, with a 
ferritin value of 1907 ng/mL. The patient never experienced 
acute or chronic GVHD. 
Rituximab (375 mg/m2/wk for 4 weeks) and rHuEPO 
40,000 U twice a week were subsequently administered 
without any significant response. The bone marrow biopsy 
performed 8 months after transplant confirmed a PRCA and 
full donor chimerism. Ten months after transplant rHuEPO 
was withdrawn because of a lack of efficacy. Viral infec- 
tions (cytomegalovirus; Epstein-Barr virus; human 
herpesvirus-6, -7, and -8; herpes simplex virus 1 and 2; and 
parvovirus B19) were excluded. 
Eleven months after the transplant the patient received 
a total of 4 doses of bortezomib (1.4 g/m2 once a week), 
however, any modification of the transfusion support and 
isohemoagglutinin titer was observed. Ferrochelation with 
DFX was withheld in February 2016 because of the pres- 
 
ence of neutropenia, and DFO was started. In December 2016 
1 dose of cyclophosphamide (1 g) was administered, without 
any relevant response. 
Based on the favorable results obtained in our previous 
patient, in June 2017 we decided to start the TPO mimetic 
eltrombopag at the dose of 75 mg/day for the first week and 
then increased to 150 mg/day. After 3 weeks of treatment 
eltrombopag was discontinued because of increased plate- 
lets up to 500,000 × 109/L and then was resumed at a dose 
ranging between 50 and 75 mg/day to maintain the platelet 
value within the normal range. 
Overall, after 5 weeks of treatment with eltrombopag the 
patient became transfusion independent, with progressive im- 
provement of hemoglobin values until normal values. After 
5 months of treatment with eltrombopag the bone marrow 
biopsy showed a moderate trilinear hyperplasia (Figure 2B). 
In December 2017 patient 2 discontinued eltrombopag after 
  
 
 
Figure 2. (A) Bone marrow biopsy shows intact granulocytic and megakaryocytic lineages. Erythroid colonies are absent. (B) Immunostaining for CD71 high- 
lights rare erythroid precursors. (C) After eltrombopag treatment, bone marrow biopsy shows a good trilinear representation with normoblastic erythropoiesis. 
(D) Immunohistochemical stain for CD71 highlights erythroid colonies. 
 
 
6 months of treatment. Levels of both hemoglobin and plate- 
lets remained within the normal range since then. Figure 1B 
shows the time course of the patient. 
 
DISCUSSION 
Eltrombopag has been proven to be an effective treat- 
ment for patients with SAA refractory to immunosuppressive 
agents [21-23]. Our preliminary data seem to indicate that 
eltrombopag is a promising drug even in unilineage 
cytopenias. PRCA is a well-recognized complication after al- 
logeneic HSCT and may be associated to severe pancytopenia 
in 16% of the cases [24]. However, no standard of care for the 
treatment of this condition has been established. Table 1 sum- 
marizes the clinical characteristics and treatment modalities 
adopted for patients with post-HSCT PRCA reported in liter- 
ature since 2000. 
Roughly 70 patients with post-HSCT PRCA have been de- 
scribed, and nearly all patients were blood group O and 
received grafts from donors of blood group A [3,6-18]. Donors 
were equally balanced between unrelated and matched 
sibling, whereas conditioning regimens were mainly 
myeloablative and GVHD prophylaxis cyclosporine-based in 
most patients. A large number of treatment modalities have 
been reported with variable degree of success. A complete 
and partial repsonses have been reported in 66% of patients 
who were treated with PEX (7/14) or EPO (7/7), in 36% of pa- 
tients who received rituximab (5/14), and in 58% of patients 
treated with high-dose steroids alone or combined with ta- 
pering of calcineurin inhibitors (11/19). Donor lymphocyte 
infusion, bortezomib, and mesenchymal stem cells have been 
reported in sporadic cases. Undoubtedly, these data may over- 
estimate the real need for aggressive treatments of patients 
with post-HSCT PRCA because of the propensity of investi- 
gators to report difficult cases and especially those who fail 
 
primary therapy such as rHuEPO. Nevertheless, erythroid 
aplasia and transfusion dependence after HSCT is a compel- 
ling problem that justifies therapeutic efforts for a timely 
solution. In this respect eltrombopag has a high curative po- 
tential with a good safety profile. 
The mechanism through which eltrombopag may have 
induced erythroid reconstitution in our patients remains spec- 
ulative. Several lines of evidence suggest that eltrombopag 
is able to stimulate directly human hematopoietic stem cells 
[22,23,25]. Desmond et al. [22] showed that in patients with 
SAA, 7 of 17 responders achieved trilineage responses and 
11 patients became RBC transfusion independent. Moreover, 
in vitro studies showed that TPO may affect proliferation and 
differentiation of erythroid progenitors and of late-stage 
erythroid precursors, respectively [26]. Alternatively, or ad- 
ditionally, the pathway that involves IFN-γ (a proinflammatory 
cytokine often increased after HSCT and potentially impli- 
cated in the damage of hematopoietic stem and progenitor 
to cells), may also be affected. Recent findings showed that 
eltrombopag was capable of evading the IFN-γ induced in- 
hibition on human hematopoietic stem and progenitor cells 
through the impairment of the TPO/c-MPL pathway [27]. 
Whether eltrombopag may affect immune cell functions is 
still a matter of investigation. 
Emerging data suggesting that ICT is able to induce an ery- 
throid response [28-32]. Messa et al. [31] reported that 42% 
of patients with hematologic malignancies and aplastic 
anemia achieved a transfusion independency after treat- 
ment with DFX or DFO. Similarly, Gattermann et al. [32] 
showed that DFX treatment for up to 1 year led to erythroid 
improvement in 21% of 247 patients with myelodysplastic 
syndrome. According to these observations, a potential syn- 
ergistic effect between ICT and eltrombopag may be 
hypothesized in our patients. In particular, patient 2 showed 
  
 
 
 
 
 
 
 
 
 
 
 
 
Table 1 
Summary of PRCA post-HSCT Reported in the Literature from 2000 to 2017 
 
Reference Patients with PRCA Diagnosis HSCT Source Conditioning GVHD Prophylaxis D/R ABO Treatment and Outcome (no. of patients) CR/PR Failure 
Sackett K. J Clin Apher 2016 1 SCN MUD BM MAC CSA A→0 PEX RTX, bortezomib, darbopoietin 
Helbig G. Ann Hematol 2007 6 AL 5/6 MSD (5) BM (3) MAC CSA-MTX (5) A→0 (4) RTX + rHuEPO (1) DLI (1) 
   MUD (1) PBSC (2)  CSA (1) Bi-D (1) rHuEPO+second HSCT + RTX (1) 
PEX (1) 
second HSCT (1) 
PDN + rHuEPO + TaperCI (1) 
PDN + rHuEPO + TaperCI + AZA (1) 
RTX (1) 
 
Fang B. Ann Hematol 2009 
 
2 
 
AL 
 
MSD (1) 
BM+PBSC (1) 
BM (1) 
 
MAC 
 
CSA-MTX (1) 
 
A→0 
PEX + rHuEPO+second HSCT (1) 
MSC (2) 
PEX (1) 
PEX ± steroids (2) 
 
Hirokawa M. BBMT 2013 
 
46 
 
AL (36) 
MUD (1) 
MSD (24) 
PBSC (1) 
BM (33) 
 
MAC (21) 
CSA-MTX-MMF (1)  
A→0 (28) 
 
CS (8/14), taperCI (2/8), RTX (1) 
RTX + rHuEPO + CS + taperCI (1) 
RTX (2), rHuEPO (3),CS (1), DLI (2), 
 
Poon L-M. BMT 2012 
 
1 
 
AML 
MUD (22) 
MSD 
PBSC (13) 
PBSC 
 
MAC 
 
Tac-MTX 
Bi-D (6) 
Bi-D 
 
Bortezomib 
 
RTX, taperCI, DLI 
Benson DM. BMT 2008 1 NHL MUD PBSC MAC NR A→0 RTX — 
Verholen F. Eur J Hematol 2004 1 AML PMRD PBSC MAC CSA-MTX A→0 DLI PEX, RTX 
Yang M-H. Ann Hematol 2001 1 SAA MSD BM MAC CSA-MTX A→0 CS — 
Yang X. Transf Med 2014 1 AML MSD PBSC MAC Tac-MMF A→0 CS — 
Deotare U. BMT 2006 1 SAA MSD PBSC RIC CSA-MTX Bi-D CS RTX, rHuEPO, taper CI 
Worel N. Transf 2000 
 
Khan F Transf Med 2014 
7 
 
1 
AL,SAA, CML 
 
MDS 
MSD 
 
MSD 
BM (6) 
PBSC (1) 
NR 
MAC 
 
RIC 
NR 
 
Tac-MTX 
A→0 
B→0 
A→0 
PEX (4) 
IA + rHuEPO (2) 
Bortezmib 
rHuEPO (5) 
 
CS + RTX 
Maschan AA, BMT 2002 1 SAA MSD  MAC CSA-MTX A→0 RTX — 
Rabitsch W. BMT 2003 5 ALL (2) 
CML (2) 
NHL (1) 
MSD NR NR CSA-MTX A→0 (4) 
B→0 (1) 
IA (5) RHuEPO (5) 
PEX (3) 
NR indicates no response; CR, complete response; PR, partial remission; SCN, severe congenital neutropenia; MSD, matched sibling donor; MUD, matched unrelated donor; PMRD, partially matched related donor; PBSC, 
peripheral blood stem cell; BM, bone marrow; MAC, myeloablative conditioning; CSA, cyclosporine; MTX, methotrexate; MMF mycophenolate mofetil; Tac, tacrolimus; RTX, rituximab; AL, acute leukemia; AML, acute myeloid 
leukemia; NHL, non-Hodgkin lymphoma; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome; ALL, acute lymphoblastic leukemia; taperCI, taper calcineurin inhibitor; IA, immunoadsorption; AZA, azathio- 
prine; Bi-D, Bidirectional; MSC, mesenchymal stem cells; DLI, donor lymphocyte transfusion; CS, corticosteroids; NR, not reported. 
 an erythroid response after 2 months of treatment with 
eltrombopag and 16 months after the start of ICT with DFO, 
which led to a significant reduction of ferritin levels. In patient 
1 the adjunctive effect of ICT to eltrombopag is question- 
able because DFX was administered for 3 months only and 
discontinued 6 months before the erythroid response was 
observed. 
Of note, eltrombopag was well tolerated by our patients, 
with only a transient thrombocytosis requiring dose adjust- 
ment. Neither patient had evidence of clonal evolution, 
although prolonged follow-up is still needed. 
In conclusion, although we cannot completely exclude a 
spontaneous improvement, our findings, albeit observed in 
a small patient subset, may be considered indicative of a fa- 
vorable effect of eltrombopag on unilineage cytopenias such 
as PRCA. Additional studies that include a large proportion 
of patients are mandatory to confirm our preliminary data. 
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